Myeloid Leukemia Clinical Trials

4 recruiting

Myeloid Leukemia Trials at a Glance

489 actively recruiting trials for myeloid leukemia are listed on ClinicalTrialsFinder across 6 cities in 52 countries. The largest study group is Phase 1 with 210 trials, with the heaviest enrollment activity in Houston, New York, and Boston. Lead sponsors running myeloid leukemia studies include M.D. Anderson Cancer Center, The First Affiliated Hospital of Soochow University, and City of Hope Medical Center.

Browse myeloid leukemia trials by phase

Treatments under study

About Myeloid Leukemia Clinical Trials

Looking for clinical trials for Myeloid Leukemia? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Myeloid Leukemia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Myeloid Leukemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 489 trials

Recruiting
Phase 2

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Acute Myeloid Leukemia
National Cancer Institute (NCI)147 enrolled220 locationsNCT06317649
Recruiting
Phase 2

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Acute Myeloid Leukemia
National Cancer Institute (NCI)153 enrolled177 locationsNCT05554393
Recruiting
Phase 1

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Leukemia, Lymphocytic, AcuteBlood CancerMyeloid Leukemia, Acute+8 more
National Cancer Institute (NCI)86 enrolled1 locationNCT06904066
Recruiting
Phase 2

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Acute Myeloid LeukemiaAcute Myeloid Leukemia Post Cytotoxic TherapyAcute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm+1 more
National Cancer Institute (NCI)335 enrolled220 locationsNCT05554406
Recruiting
Phase 2

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Acute Myeloid LeukemiaMyelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+2 more
National Cancer Institute (NCI)2,000 enrolled346 locationsNCT05564390
Recruiting
Phase 2Phase 3

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Acute Myeloid LeukemiaMyelodysplastic SyndromesChronic Myelomonocytic Leukemia+1 more
Taiho Oncology, Inc.316 enrolled71 locationsNCT04256317
Recruiting

Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants

Acute Myeloid LeukemiaMyelodysplastic SyndromesGermline Mutation
National Cancer Institute (NCI)510 enrolled1 locationNCT07019155
Recruiting
Phase 1

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

Acute Myeloid LeukemiaMyelodysplastic Syndromes
Taiho Oncology, Inc.18 enrolled21 locationsNCT04953897
Recruiting
Phase 1

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

Acute Myeloid LeukemiaMyelodysplastic Syndromes
Taiho Oncology, Inc.27 enrolled22 locationsNCT04953910
Recruiting
Phase 1Phase 2

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

Myeloid Leukemia, Philadelphia Positive
Novartis Pharmaceuticals34 enrolled39 locationsNCT04925479
Recruiting
Phase 2

Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid LeukemiaRelapse/Recurrence
Shenzhen University General Hospital10 enrolled1 locationNCT07563179
Recruiting

Design and Validation of a Generative AI and Propensity Score Matching Model for the VEN-DEC Phase II Study in Elderly AML Eligible for Allo-SCT; Evaluation of an Exploratory Approach Respect to a Randomized Phase III Trial

Acute Myeloid Leukemia
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia1,941 enrolled1 locationNCT07420790
Recruiting
Phase 3

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia
PedAL BCU, LLC130 enrolled89 locationsNCT05183035
Recruiting
Phase 4

Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3).

Acute Myeloid LeukemiaChemotherapy EffectNewly Diagnosed
Fujian Medical University Union Hospital100 enrolled1 locationNCT07561892
Recruiting
Phase 1

Efficacy and Safety of Autologous Peptide-induced Active Immunity in AML Maintenance Therapy

Acute Myeloid LeukemiaMaintenance TherapyPersonalized Active Immunotherapy
Fujian Medical University Union Hospital90 enrolled1 locationNCT07551037
Recruiting
Phase 1

Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMyelodysplastic Syndrome
City of Hope Medical Center33 enrolled1 locationNCT06195891
Recruiting
Phase 1

A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia
M.D. Anderson Cancer Center40 enrolled1 locationNCT06191978
Recruiting
Phase 1

CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid LeukemiaRelapsed/Refractory T-cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University25 enrolled1 locationNCT06696846
Recruiting
Phase 2

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Acute Myeloid Leukemia
National Cancer Institute (NCI)93 enrolled122 locationsNCT06672146
Recruiting
Phase 2

Ivosidenib as Post-HSCT Maintenance for AML

Acute Myeloid Leukemia (AML)IDH1 MutationHematopoietic Stem Cell Transplant (HSCT)
Massachusetts General Hospital75 enrolled4 locationsNCT06707493